Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Can-Fite Biopharma Ltd ADR (NY: CANF ) 1.980 +0.060 (+3.13%) Official Closing Price Updated: 8:00 PM EDT, Apr 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 8,665 Open 2.000 Bid (Size) 1.830 (1) Ask (Size) 2.060 (1) Prev. Close 1.920 Today's Range 1.910 - 2.010 52wk Range 1.705 - 3.330 Shares Outstanding 515,746,293 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 12 Health Care Stocks Moving In Thursday's Pre-Market Session April 25, 2024 Via Benzinga Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal April 25, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Performance YTD -4.35% -4.35% 1 Month -10.81% -10.81% 3 Month -5.71% -5.71% 6 Month -1.49% -1.49% 1 Year +13.79% +13.79% More News Read More Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH April 15, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can Fite Biofarma: Q4 Earnings Insights March 28, 2024 Via Benzinga Recap: Can Fite Biofarma Q3 Earnings November 30, 2023 Via Benzinga Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients April 03, 2024 From Can-Fite BioPharma Ltd. Via Business Wire CANF Stock Earnings: Can Fite Biofarma Beats EPS, Beats Revenue for Q4 2023 March 28, 2024 Via InvestorPlace Can-Fite Reports 2023 Financial Results and Clinical Update March 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference March 11, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada February 28, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication January 30, 2024 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study January 29, 2024 From Can-Fite BioPharma Ltd. Via Business Wire The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies December 20, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan December 18, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development December 04, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update November 30, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Why Is Liver Cancer Focused Can-Fite BioPharma Stock Trading Higher Today? November 21, 2023 Via Benzinga Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson November 21, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track November 01, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action October 30, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs October 26, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday October 24, 2023 Via Benzinga Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies October 09, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR) September 27, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference September 07, 2023 From Can-Fite BioPharma Ltd. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.